Beam Therapeutics Inc.
BEAM
$26.75
$0.240.91%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -94.21% | 324.87% | 279.52% | -32.03% | -28.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -94.21% | 324.87% | 279.52% | -32.03% | -28.08% |
| Cost of Revenue | -6.55% | 5.78% | -2.14% | 16.46% | 16.91% |
| Gross Profit | -1.41% | 20.32% | 120.78% | -25.11% | -23.94% |
| SG&A Expenses | 18.94% | 23.22% | 12.63% | 0.85% | -9.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.22% | 9.62% | 1.11% | 13.03% | 10.24% |
| Operating Income | -5.33% | 10.12% | 82.56% | -19.07% | -14.54% |
| Income Before Tax | -20.11% | 12.93% | 370.38% | -16.61% | -12.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.11% | 12.93% | 370.38% | -16.61% | -12.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.11% | 12.93% | 370.38% | -16.61% | -12.18% |
| EBIT | -5.33% | 10.12% | 82.56% | -19.07% | -14.54% |
| EBITDA | -5.70% | 10.68% | 87.55% | -20.02% | -15.40% |
| EPS Basic | -17.43% | 25.82% | 317.68% | 6.31% | 9.47% |
| Normalized Basic EPS | -13.13% | 23.92% | 324.09% | -0.46% | -0.90% |
| EPS Diluted | -17.43% | 25.82% | 313.43% | 6.31% | 9.47% |
| Normalized Diluted EPS | -13.13% | 23.92% | 319.71% | -0.46% | -0.90% |
| Average Basic Shares Outstanding | 2.29% | 17.38% | 24.21% | 24.46% | 23.91% |
| Average Diluted Shares Outstanding | 2.29% | 17.38% | 26.69% | 24.46% | 23.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |